Fox Run Management L.L.C. Invests $1.59 Million in Encompass Health Co. (NYSE:EHC)

Fox Run Management L.L.C. acquired a new stake in shares of Encompass Health Co. (NYSE:EHC) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 17,240 shares of the company’s stock, valued at approximately $1,592,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. CIBC Asset Management Inc raised its holdings in Encompass Health by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock worth $286,000 after acquiring an additional 100 shares during the last quarter. Miracle Mile Advisors LLC raised its stake in shares of Encompass Health by 3.0% in the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock worth $354,000 after purchasing an additional 112 shares during the last quarter. US Bancorp DE boosted its position in shares of Encompass Health by 9.6% during the fourth quarter. US Bancorp DE now owns 1,380 shares of the company’s stock valued at $127,000 after buying an additional 121 shares during the last quarter. Signaturefd LLC increased its holdings in Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company’s stock worth $65,000 after buying an additional 125 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC raised its position in Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after buying an additional 127 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 2.1 %

Shares of NYSE:EHC opened at $97.05 on Friday. The stock has a 50 day moving average of $97.98 and a 200 day moving average of $97.10. The company has a market cap of $9.77 billion, a PE ratio of 21.76, a price-to-earnings-growth ratio of 2.31 and a beta of 0.92. Encompass Health Co. has a 12-month low of $76.11 and a 12-month high of $104.55. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date is Tuesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is 15.25%.

Insider Buying and Selling

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. KeyCorp lifted their price target on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. Barclays upped their price objective on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $110.00 price target on shares of Encompass Health in a research note on Tuesday, February 11th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Encompass Health has an average rating of “Buy” and an average price target of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.